BECTON DICKINSON AND CO
BDXNYSETrading Snapshot
- Day Range
- $179.38 β $181.83
- 52-Week Range
- $127.59 β $193.07
- Volume
- $4.56B
- Avg Volume
- $4.64B
- Shares Outstanding
- 275.5M
- Next Earnings
- Nov 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $21.84B
- Last Q Revenue
- $4.98B
- P/E Ratio
- 52.9
- P/S Ratio
- 2.4x
- EPS (TTM)
- $3.31
- Dividend Yield
- 2.35%
- Dilution (1yr)
- β1.8%
Why Investors Own BDX
- βHigh-growth profile β revenue up +58.3% YoY with expanding US Equity exposure.
- βHealthy economics β 26% gross margin and 17% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
BECTON DICKINSON AND CO
BDXAbout BECTON DICKINSON AND CO
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates

3 Historically Stable Dividend Raisers in Medical Devices Offering Solid Yields With Fortress-Like Growth
Pacemakers and glucose monitors keep selling whether the economy booms or collapses, and three medical device giants have spent decades turning that predictable demand into paychecks that grow every single year.

BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
Generations of Utah employees have helped ensure the reliable supply of essential medical devices that clinicians use every day to care for patients around the world SANDY, Utah, Sept. 29, 2026 /PRNewswire/ -- BD (Becton
Here's Why You Should Retain BDX Stock in Your Portfolio for Now
Becton, Dickinson's MedTech transformation, innovation pipeline and strategic partnerships support growth despite reimbursement and macroeconomic pressures.

Best Dividend Kings: September 2026
Dividend Kings are underperforming SPY in September, with a -4.22% average return versus SPY's marginal gain. Despite aggregate weakness, 29 Dividend Kings appear both undervalued and offer a long-term expected return of

Engineers Gate Manager LP Buys New Shares in Becton, Dickinson and Company $BDX
Engineers Gate Manager LP purchased a new position in Becton, Dickinson and Company (NYSE: BDX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fu

Arthur Hu to Join BD as Chief Information and Digital Officer
FRANKLIN LAKES, N.J., Sept. 21, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Arthur (Art) Hu has been named executive vice preside